NNBXF Nanobiotix S.A.
Price Chart
Executive Summary
Nanobiotix announced the full exercise of the underwriters' over-allotment option in its global offering, increasing total gross proceeds to approximately $100 million. The offering includes 2,218,467 ordinary shares and 345,099 pre-funded warrants, with proceeds expected to fund operations into 2029. This follows a preliminary prospectus supplement filed two days ago that signaled massive potential dilution, though the actual offering size is far smaller than the 75 million shares initially registered.
Actionable Insight
The capital raise provides cash runway into 2029, removing near-term financing risk, but the 14.92% discount and dilution are negative for existing holders. The actual offering size (2.2M shares + 345K warrants) is far smaller than the 75M shares initially registered, which may relieve some overhang fears. Monitor for any further secondary offerings and clinical data readouts for JNJ-1900 (NBTXR3) and Nanoprimer platforms.
Key Facts
- Underwriters fully exercised over-allotment option for 33,805 additional ADSs at $38.98/ADS
- Total gross proceeds from global offering now approximately $100 million
- Total securities issued: 2,218,467 ordinary shares and 345,099 pre-funded warrants
- Offering priced at €33.60 per ordinary share, a 14.92% discount to VWAP over prior three trading sessions
- Net proceeds expected to fund operations into 2029
- Proceeds allocation: <10% to JNJ-1900 (NBTXR3), 50-60% to Nanoprimer and other platforms, 30-40% for general corporate purposes
- This follows a preliminary prospectus supplement on May 20 for up to 75 million shares (~155% dilution), though actual offering is much smaller
Financial Impact
Approximately $100 million gross proceeds raised, with ~4.5% dilution from the base offering plus additional 33,805 ADSs from over-allotment. The 14.92% discount to recent VWAP represents a material cost to existing shareholders.
Risk Factors
- Dilution from the offering and pre-funded warrants reduces EPS and ownership percentage for existing shareholders
- 14.92% discount to VWAP signals weak demand at market price
- Proceeds heavily weighted toward early-stage Nanoprimer platform (50-60%), which carries higher clinical risk
- Potential for additional offerings if cash burn accelerates or clinical milestones are delayed
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003653 |
| Document: f6k_052226.htm | 0001171843-26-003653 |
| Document: 0001171843-26-003653-index-headers.html | 0001171843-26-003653 |
| Document: 0001171843-26-003653-index.html | 0001171843-26-003653 |
| Document: 0001171843-26-003653.txt | 0001171843-26-003653 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
6-K
| — | awaiting T+20 | — | — |
|
Jun 2, 2026
7d ago
|
6-K
| — | awaiting T+20 | — | — |
|
May 26, 2026
14d ago
|
6-K
| — | awaiting T+20 | — | — |
|
May 26, 2026
14d ago
|
6-K
| — | awaiting T+20 | — | — |
|
May 22, 2026
18d ago
|
6-K
| — | awaiting T+20 | — | — |
|
May 22, 2026
18d ago
|
424B5
| — | awaiting T+20 | — | — |
|
May 21, 2026
19d ago
|
6-K
| — | awaiting T+20 | — | — |
|
May 21, 2026
19d ago
|
6-K
| — | awaiting T+20 | — | — |
|
May 20, 2026
20d ago
|
6-K
| — | awaiting T+20 | — | — |
|
May 20, 2026
20d ago
|
424B5
| — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access